Invizyne Technologies (IZTC) Competitors $9.31 -0.48 (-4.85%) As of 08/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IZTC vs. TLSA, ALMS, ALLO, GALT, AARD, TVRD, ACIU, CRGX, AVTE, and PRQRShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Tiziana Life Sciences (TLSA), Alumis (ALMS), Allogene Therapeutics (ALLO), Galectin Therapeutics (GALT), Aardvark Therapeutics (AARD), Tvardi Therapeutics (TVRD), AC Immune (ACIU), CARGO Therapeutics (CRGX), Aerovate Therapeutics (AVTE), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. Invizyne Technologies vs. Its Competitors Tiziana Life Sciences Alumis Allogene Therapeutics Galectin Therapeutics Aardvark Therapeutics Tvardi Therapeutics AC Immune CARGO Therapeutics Aerovate Therapeutics ProQR Therapeutics Tiziana Life Sciences (NASDAQ:TLSA) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment. Is TLSA or IZTC more profitable? Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Invizyne Technologies N/A N/A N/A Does the media favor TLSA or IZTC? In the previous week, Tiziana Life Sciences and Tiziana Life Sciences both had 1 articles in the media. Tiziana Life Sciences' average media sentiment score of 0.87 beat Invizyne Technologies' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invizyne Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation and earnings, TLSA or IZTC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$11.86MN/AN/AInvizyne TechnologiesN/AN/AN/AN/AN/A SummaryTiziana Life Sciences beats Invizyne Technologies on 1 of the 1 factors compared between the two stocks. Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.21M$283.48M$5.82B$9.74BDividend YieldN/AN/A3.84%4.09%P/E RatioN/AN/A31.1525.97Price / SalesN/A563.89475.57123.18Price / CashN/A22.4437.1558.38Price / BookN/A10.439.116.39Net IncomeN/A-$115.81M$3.26B$265.66M7 Day Performance-6.81%-0.61%2.11%1.98%1 Month Performance0.65%-4.58%5.12%1.33%1 Year PerformanceN/A-8.01%31.25%21.15% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$9.31-4.9%N/AN/A$58.21MN/A0.0029News CoverageGap DownTLSATiziana Life Sciences0.6787 of 5 stars$2.07-6.9%N/A+52.6%$242.46MN/A0.008ALMSAlumis3.0655 of 5 stars$4.38-1.9%$19.80+352.5%-64.6%$238.86MN/A0.00N/AALLOAllogene Therapeutics2.878 of 5 stars$1.07+3.4%$8.44+692.9%-59.1%$232.95M$20K-0.87310GALTGalectin Therapeutics2.2833 of 5 stars$3.64-3.6%$6.00+65.1%+66.5%$230.06MN/A-5.059AARDAardvark TherapeuticsN/A$10.55+5.1%$33.00+212.8%N/A$228.94MN/A0.0018News CoverageAnalyst RevisionTVRDTvardi Therapeutics1.3287 of 5 stars$24.45+3.6%$64.25+162.8%N/A$228.85M$7.14M0.0080News CoveragePositive NewsGap UpACIUAC Immune1.7472 of 5 stars$2.22+3.3%$12.00+440.5%-37.5%$222.91M$28.92M-3.83140Positive NewsCRGXCARGO Therapeutics2.1327 of 5 stars$4.47+0.1%$15.40+244.9%N/A$215.93MN/A-0.96116Positive NewsAVTEAerovate TherapeuticsN/A$7.40-1.2%N/A-88.8%$214.49MN/A-2.4720Gap UpHigh Trading VolumePRQRProQR Therapeutics2.6881 of 5 stars$2.03+6.0%$8.00+295.1%+5.2%$213.05M$20.46M-4.40180 Related Companies and Tools Related Companies Tiziana Life Sciences Alternatives Alumis Alternatives Allogene Therapeutics Alternatives Galectin Therapeutics Alternatives Aardvark Therapeutics Alternatives Tvardi Therapeutics Alternatives AC Immune Alternatives CARGO Therapeutics Alternatives Aerovate Therapeutics Alternatives ProQR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IZTC) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access